Metagenomi (MGX) Projected to Post Quarterly Earnings on Monday

Metagenomi (NASDAQ:MGX) will likely be announcing its Q4 2025 results before the market opens on Monday, March 16th. Analysts expect the company to announce earnings of ($0.58) per share for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 5, 2026 at 3:00 PM ET.

Metagenomi (NASDAQ:MGX) last released its quarterly earnings results on Thursday, March 5th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.02). The firm had revenue of $3.91 million during the quarter, compared to analysts’ expectations of $7.33 million. Metagenomi had a negative return on equity of 47.14% and a negative net margin of 348.54%. On average, analysts expect Metagenomi to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Metagenomi Trading Down 8.1%

Shares of MGX stock opened at $1.48 on Monday. Metagenomi has a 12-month low of $1.23 and a 12-month high of $3.95. The business’s fifty day simple moving average is $1.59 and its 200-day simple moving average is $1.93. The company has a market cap of $55.57 million, a PE ratio of -0.62 and a beta of 0.45.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Metagenomi in a research note on Monday, December 22nd. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $10.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in MGX. BNP Paribas Financial Markets lifted its stake in shares of Metagenomi by 1,840.0% during the third quarter. BNP Paribas Financial Markets now owns 15,171 shares of the company’s stock worth $36,000 after buying an additional 14,389 shares during the period. Bank of America Corp DE increased its position in shares of Metagenomi by 508.5% in the 3rd quarter. Bank of America Corp DE now owns 18,766 shares of the company’s stock valued at $44,000 after acquiring an additional 15,682 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in Metagenomi in the 3rd quarter worth $64,000. Panagora Asset Management Inc. purchased a new position in Metagenomi in the 4th quarter worth $53,000. Finally, Quadrature Capital Ltd acquired a new stake in Metagenomi during the 4th quarter worth about $55,000.

Metagenomi Company Profile

Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.